Prolyl hydroxylase (PHD) as a therapeutic target for metformin-associated lactic acidosis (MALA)
Tomoko Oyaizu-Toramaru(Keio University), Yoji Andrew Minamishima(Cincinnati Children's Hospital Medical Center), Shizuka Minamishima(Cincinnati Children's Hospital Medical Center), Takako Hishiki(Keio University), Hiroshi Morisaki(Keio University), Noriyo Hayakawa(Keio University), Takashi Nakamura(Keio University), Kyoji Yamaguchi(Daiichi-Sankyo (Japan)), Tomohiro Suhara(University of Hawaiʻi at Mānoa), Makoto Suematsu(Central Institute for Experimental Animals)
The Molecular Biology Society of Japan
November 8, 2016
Cited by 0
Related Papers
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
|Proceedings of the National Academy of Sciences|1998|4.3k
Tumor Necrosis Factor α Stimulates Osteoclast Differentiation by a Mechanism Independent of the Odf/Rankl–Rank Interaction
|The Journal of Experimental Medicine|2000|1.3k
Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis<i>in Vitro</i><sup>1</sup>
|Endocrinology|1998|1.2k
Distinct Metabolic Flow Enables Large-Scale Purification of Mouse and Human Pluripotent Stem Cell-Derived Cardiomyocytes
|Cell stem cell|2012|1.1k
RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
|Biochemical and Biophysical Research Communications|1998|746